Ajinomoto Co., Ltd.

Japan As Represented by Director General of Agency of National Institute

Yoshitomo Chujo

Akihiro Yamazaki

Kazuhiro Matsuo

Hiromichi Tasaka

Shudo Yamazaki

Mitsuo Honda

Yasuhiro Tanaka

Manabu Suzuki

Masahiro Murata

Tadakiyo Nakagawa

Tatsuhiro Yamada

Kohichi Fujita

Yuka Ikenoue

Tomoyuki Tagami

Shunsuke Fukuda

The inventive subject matter relates to compounds, pharmaceutical compositions, and kits containing a heterocyclic compound represented by the formula (I) wherein R is an alkyl group optionally having substituent(s) etc., X is an amino group optionally having substituent(s), Yand Yare nitrogen atoms etc., an isomer or solvate thereof or a pharmaceutically acceptable salt thereof as an active ingredient.

Heterocyclic compounds

A vaccine containing Mycobacterium bovis BCG which secretes a fusion protein to be obtained by inserting a foreign antigen peptide into the molecular surface of a secretory protein, a carrier, having a signal peptide. BCG constituting the present invention secretes a fusion protein to be obtained by inserting a foreign antigen peptide into the molecular surface of an .alpha.-antigen derived from mycobacteria. Said fusion protein has significantly increased antigenicity and immunogenicity. Therefore, when it is inoculated into animals, it is efficiently recognized by B cells which recognize said antigen, thereby effectively inducing the production of an antibody to said antigen. When said BCG itself is inoculated into animals, it continuously secretes said fusion protein in the bodies of the animals while continuously propagating therein. Therefore, said BCG is an extremely useful vaccine.

Anti-AIDS secretory recombinant BCG vaccine

Anti-acids secretory recombinant BCG vaccine

Growing community of inventors

Kawasaki, Japan

Yoshitomo Chujo